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In cell line studies, BCL-2, BAX, as well as novel MEK1 protein levels have strong influence on ovarian cancer response to cisplatin-
based chemotherapy. However, such associations have not been demonstrated clinically. We evaluated prognostic/predictive
significance of these proteins with regard to TP53 status. Immunohistochemical analysis was performed on 229 ovarian carcinomas
FIGO stage IIB–IV treated with platinum-based chemotherapy; the results were analysed by the Cox and logistic regression models.
Clinical parameters (residual tumour size, patient age, FIGO stage) were the only indicators of overall survival (OS) and the strongest
predictors of complete remission (CR). On the other hand, BAX expression was the strongest (P¼0.005) or the only (in FIGO IIIC,
P¼0.02) prognostic indicator of disease-free survival (DFS) in the TP53(+) group. TP53(+) and TP53( ) ovarian carcinomas
differed in clinical and molecular prognostic and predictive factors. Another novel finding is that CR was negatively influenced by high
BAX expression in all patients group (P¼0.047) and by BCL2 expression in the TP53( ) group (P¼0.05). High MEK1 expression
was associated with endometrioid and clear cell carcinomas (P¼0.049); its loss was found with advancing FIGO stage (P¼0.002).
Our results suggest that binomial TP53 status divides ovarian carcinomas into two biologically distinct groups. BAX expression is an
important factor of DFS in the TP53(+) group. BCL-2 and BAX, but not MEK1 expressions have predictive value in ovarian cancer
patients treated with platinum-based chemotherapy.
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Cisplatin is the most commonly used chemotherapeutic compound
in ovarian cancer patients and resistance to it is a major clinical
problem in this condition (Christian and Trimble, 1994).
Apoptosis is a predominant mechanism of tumour cell loss during
chemotherapy, and its inefficiency may be an important cause of
chemoresistance. Cisplatin induces apoptosis, which in a majority
of ovarian carcinoma cell lines is TP53-dependent (Jones et al,
1998; Shimada et al, 2000). Impaired TP53 protein function, most
frequently reflecting TP53 gene mutation contributes to resistance
to cisplatin in ovarian carcinoma cell lines (Herod et al, 1996;
Jones et al, 1998; Shimada et al, 2000), and the same could be
expected clinically. Despite high frequency of TP53 gene mutations
in ovarian carcinomas (Kupryjan ´czyk et al, 1993; 2000; Casey et al,
1996; DiCioccio et al, 1998; Wen et al, 1999), studies on TP53
status and tumour response to cisplatin-based chemotherapy have
not so far given equivocal results (Righetti et al, 1996; de Feudis
et al, 1997; Baekelandt et al, 1999; Eisenhauer et al, 1999; Fallows
et al, 2001; Reles et al, 2001).
TP53 cooperates with apoptosis-regulating proteins in tumour
response to cisplatin-based chemotherapy. BCL-2 expression (an
apoptosis inhibitor) is downregulated, while BAX expression (an
apoptosis promoter) is upregulated by TP53 protein (Miyashita
et al, 1994; Miyashita and Reed, 1995). It has also been shown that
cisplatin-induced apoptosis is associated with wild-type TP53/BAX
complex formation (Raffo et al, 2000). Cell line studies show that
TP53-regulated protein levels may differ constitutionally and/or
after cisplatin administration depending on the functional TP53
status (Herod et al, 1996; Jones et al, 1998). Thus, in multivariate Revised 19 June 2002; accepted 19 November 2002
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yanalyses of prognostic and/or predictive factors, evaluating
tumours together with functional and dysfunctional TP53
protein may possibly mask the biological significance of proteins
regulated by or interacting with wild-type TP53 but not with
mutant TP53.
Studies on ovarian carcinoma cell lines have revealed an
association between high BCL-2 levels and resistance to cisplatin
(Eliopoulos et al, 1995; Herod et al, 1996; Jones et al, 1998),
however, contradictory results have been published, too
(Beale et al, 2000); BAX expression either enhanced or did not
influence ovarian carcinoma cell lines sensitivity to cisplatin
(Jones et al, 1998; Beale et al, 2000). Despite these findings,
significance of BCL-2 or BAX expression in ovarian cancer
response to cisplatin-based chemotherapy has not been confirmed
by clinical studies.
MEK is a relatively recently described apoptosis inhibitor. MEK
(MEK1/MEK2 isoforms) is a MAP kinase kinase that plays a role in
signal transduction from growth factors in a receptor tyrosine
kinase – RAS–RAF–MEK–ERK cascade (Garrett and Workman,
1999). This cascade transmits both mitogen and antiapoptotic
signals. It has been shown that MEK may stimulate antiapoptotic
BCL-2, BCL-XL and MCL-1 proteins (Boucher et al, 2000), as well
as inactivate proapoptotic protein BAD (Scheid and Duronio,
1998). Cell line studies on the role of MEK kinase in tumour
response to cisplatin-based chemotherapy are controversial: in
some studies MEK1 inhibited (Hong et al, 1999), in others
activated TP53-dependent apoptosis after cisplatin administration;
in the latter case the apoptosis was completely blocked by MEK1
inhibitors (Ryan et al, 2000; Wang et al, 2000).
Analyses of TP53 and/or apoptosis proteins in large groups of
ovarian carcinomas are rare (Hartmann et al, 1994; Eltabbakh et al,
1997; Marx et al, 1997; Baekelandt et al, 1999, 2000; Ferrandina
et al, 1999). To our knowledge, MEK1 expression and its clinical
significance have not been evaluated yet in ovarian carcinomas. In
this study, we present an analysis of the clinical significance of
TP53 accumulation and expression of proteins interacting with
TP53 in tumour response to cisplatin, that is BCL-2, BAX and
MEK1. We also present an alternative approach to the analysis of
prognostic and predictive factors in ovarian carcinomas by
eliminating variability of the TP53 status.
MATERIALS AND METHODS
Patients and tumours
The study was performed on archival ovarian carcinomas from 229
patients treated in eight gynaecologic oncology centres in Poland.
The material was carefully selected out of 548 cases submitted to
meet the following criteria: no chemotherapy before staging
laparotomy, adequate staging procedure, FIGO stage IIB to IV,
standard CP (cisplatin–cyclophosphamide or carboplatin–cyclo-
phosphamide) or CAP chemotherapy (CP with addition of
doxorubicin), and tumour tissue from the first laparotomy
available. Medical records were critically reviewed by at least two
clinicians. Patients ranged in age 24–77 years (median 53.2).
Tumours were staged according to the criteria of the International
Federation of Gynaecologists and Obstetricians (Creasman, 1989)
(Table 1). All tumours were uniformly reviewed histopathologi-
cally, classified according to the criteria of the World Health
Organization (Russell, 1994) and graded in a four-grade scale
according to the criteria given by (Barber et al, 1975) (Table 1).
Follow-up time was stated on the basis of patient’s date of death
or the last information present in medical records. Follow-up time
ranged 1.44–146.7 months (median 24.7) and 168 patients have
died (73%). Follow-up time for the group of still alive patients
ranged 7–146.7 months (median 41). Patients outcome is shown in
Table 1.
Evaluation of clinical response to chemotherapy
Response to chemotherapy was evaluated retrospectively accord-
ing to the World Health Organization response evaluation criteria
(Miller et al, 1981). The evaluation was based on data from medical
records describing patient’s clinical condition and CA125 levels in
3–4 week intervals. Complete remission (CR) was defined as dis-
appearance of all clinical and biochemical symptoms of ovarian cancer
evaluated after completion of first-line chemotherapy and confirmed
at 4 weeks. Within the CR group we have defined a platinum-
sensitive (PS) group (disease-free survival (DFS) longer than 6 months,
99 patients). The other tumours (partial remission – PR,
Table 1 Tumour characteristics in the TP53-negative and TP53-positive
group
TP53(–)
N=94
TP53(+)
N=135 P-value
a
Age
Range 24–76 25–77 0.57
mean (s.d.) 52.4 (11.1) 53.7 (9.9)
FIGO stage
IIB 4 (4%) 6 (4%)
IIC 2 (2%) 5 (4%)
IIIA 4 (4%) 4 (3%) 0.8
IIIB 19 (20%) 26 (19%)
IIIC 51 (54%) 78 (58%)
IV 14 (15%) 16 (12%)
Residual tumour
0–2cm 44 (47%) 65 (48%) 0.92
>2cm 50 (53%) 70 (52%)
Histological type
Serous 63 (67%) 114 (84%)
Endometrioid 9 (10%) 5 (4%) 0.001
Clear cell 12 (13%) 0
Undifferentiated 5 (5%) 8 (7%)
Other 5 (5%) 7 (5%)
Histological grade
G2 19 (20%) 11 (8%)
G3 55 (59%) 87 (64%) 0.032
G4 20 (21%) 37 (27%)
Chemotherapy
CP 70 (75%) 95 (70%)
CAP 24 (25%) 40 (30%)
Response to chemotherapy
Complete remission 46 (49%) 74 (55%)
Partial remission 11 (12%) 24 (18%)
No change 4 (4%) 4 (3%)
Progression 33 (35%) 33 (24%)
Platinum resistant 53 (56%) 77 (57%)
Platinum sensitive 41 (44%) 58 (43%)
Recurrence rate in
a CR group
34/46 (74%) 58/74 (78%)
Outcome
NED 12 (13%) 23 (17%)
AWD 9 (10%) 17 (13%)
DOD 70 (75%) 94 (70%)
DOC 3 (3%) 1 (1%)
CP=cyclophosphamide and cisplatin, CAP=CP plus doxorubicin, CR=complete
remission, NED=no evidence of disease, AWD=alive with disease, DOD=died of
disease, DOC=died of other causes,
aw
2 test.
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DFS shorter than 6 months were described as resistant to cisplatin
(Christian and Trimble, 1994) (Table 1).
Immunohistochemical analysis
All immunohistochemical stainings were performed on paraffin-
embedded material after heat-induced epitope retrieval (HIER).
Owing to the multicenter origin of paraffin blocks, all tumours
were checked as to the immunoreactivity by staining for vimentin.
Intratumoural inflammatory infiltrate stained for BCL-2 and BAX
was a control for tissue immunoreactivity, too. We used PAb1801
monoclonal antibody (1:500, Sigma-Genosys, Cambridge, UK) for
TP53 protein, anti-MEK1 (clone H-8) and anti-BAX (clone B-9)
monoclonal antibodies (both 1:80, Santa Cruz Biotechnology Inc,
Santa Cruz, USA), anti-BCL-2 monoclonal antibody (1:80, clone
124, Dako, Glostrup, Denmark) and antivimentin monoclonal
antibody (1:50, clone V9, Immunotech, Marseille, France).
Deparaffinised sections were boiled in a citrate buffer (pH 6.0) at
700W in a microwave: 2 5min for TP53 and vimentin, 3 5min
for BCL-2 and 6 5min for BAX; for MEK1 detection, the sections
were boiled in the same buffer for 30s at 1201C and 15psi in an
autoclave. Nonspecific tissue and endogenous peroxidase reactiv-
ity were blocked with 10% BSA and 3% H2O2, respectively. Tissue
sections were incubated with primary antibodies for 1h at room
temperature (antivimentin, anti-BCL-2 and anti-TP53) or over-
night at 4
oC (the other). Biotinylated goat anti-mouse IgG (1:1500,
cat. no. 816), peroxidase-conjugated streptavidin (1:500, cat. no.
309) (both from Immunotech, Marseille, France) and DAB were
used as a detection system. Ovarian carcinomas with and without
TP53 gene mutation were controls for TP53. Intratumoural
lymphocytes and plasma cells, as well as a tonsil tissue were
controls for BCL-2 and/or BAX. Normal salpingeal mucosa from
three cases studied served as a positive control for MEK1; anti-
WAF1 monoclonal antibody from the same company as anti-
MEK1, detecting a nuclear antigen served as an isotype-matched
antibody for anti-MEK1. Normal mouse IgG of the same subclasses
and concentrations as the primary antibodies served as negative
controls, too.
Semiquantitative evaluation of immunohistochemical stainings
was performed independently by two pathologists (JK, TSZ). TP53
protein accumulation was described as present (more than 10% of
positive cells) or absent. BAX and MEK1 expressions were
described as: (1) negative, trace or weak (further called low),
(2) moderate and (3) strong (both further called high). BCL-2
expression was described as: (1) negative or focal, and (2)
positive.
Statistical analysis
Probability of survival and DFS were estimated using the Kaplan–
Meier method (Kaplan and Meier, 1958). Overall and DFS time
analyses were performed with multivariate Cox’s proportional
hazards models (Cox, 1972); tumour response to chemotherapy
(probability of CR, probability of PS response) was evaluated with
the multivariate logistic regression model. Important factors were
selected using backward selection technique, where factors not
significant at 0.1 were drawn one by one out of the model. The
analysis was performed in all ovarian carcinomas, and separately
in the TP53( ) and TP53(+) subgroups. To eliminate an influence
of stage parameter, we evaluated separately FIGO IIIC group, too.
Associations between protein expressions and histological type,
grade, FIGO stage and residual tumour size were studied by w
2 test
(Mehta and Patel, 1983). All tests were two-sided and the level of
significance was set at 5%. All calculations were done using the
STATA 6.0 program.
RESULTS
TP53, BCL-2, BAX and MEK1 associations
TP53 protein accumulation was observed in malignant cells only,
while the other proteins, that is BCL-2, BAX and MEK1 were
expressed by normal cells or tissues, as well. In particular, MEK1
protein was expressed by mucosa of the uterine tube and
inconstantly by fibroblasts and mesothelium. BCL-2 showed
heterogeneous, cytoplasmic staining; BAX and MEK1 showed
cytoplasmic rather homogeneous staining.
TP53 protein nuclear accumulation was present in 135 (59%)
tumours. BCL-2 was negative in majority of cases (N¼156; 68%);
it was positive in 73 cases (32%). BAX expression was low in 85
(37%) cases; it was moderate in 57 (25%) and strong in 87 (38%)
cases. MEK1 expression was low in 52 tumours (23%); it was
moderate in 98 (43%) and strong in 79 (34%) tumours (Figure 1).
BCL-2, BAX and MEK1 protein expressions were not associated
with each other, neither with TP53 protein accumulation.
Associations of protein expressions with histological tumour
types are shown in Table 2. Poor tumour differentiation/
undifferentiation was associated with TP53 protein accumulation
(P¼0.032) and high BAX positivity (P¼0.018). BCL-2 and MEK1
expressions did not correlate with tumour grade.
Loss of intensity of MEK1 expression was apparent concomi-
tantly with advancing FIGO stage (100% high positivity for IIB and
IIC, 91% for IIIA and IIIB, 70% for IIIC and IV) (P¼0.002). Other
protein expressions did not correlate with FIGO stage.
Overall survival analysis
Overall survival was associated with clinical parameters and not
with any protein expression studied. Overall survival in the whole
group was influenced by patient age, FIGO stage and residual
Figure 1 Strong cytoplasmic MEK1 expression in an endometrioid
carcinoma of the ovary (haematoxylin counterstain,  250).
Table 2 Associations of protein expressions with histological tumour
types
Serous
(%)
Undifferentiated
and other (%)
Endometrioid
and clear cell (%) P-value
TP53 positive 66 61 30 0.001
BCL-2 positive 27 28 62 0.003
BAX highly
positive
59 85 65 0.043
MEK1 highly
positive
75 77 96 0.049
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ytumour (RT) size (Table 3). In addition, risk of death was higher in
cases with endometrioid and clear cell-type carcinoma of the ovary
when compared with the serous ones.
Overall survival analysis in the TP53(+) and TP53( ) subgroups
revealed two prognostically different classes of ovarian carcinomas
(Table 3; only variables showing associations in at least one
analysis are shown in the tables). Overall survival was negatively
associated with higher patient age and larger RT in the TP53(+)
group, but not in the TP53( ) group. FIGO stage influenced OS in
the TP53( ) group, but not in the TP53(+) group.
Chemotherapy with the addition of doxorubicin compared with
CP regimen showed a tendency to increased risk of death in all
patients group (P¼0.07) (Table 3). It turned out in further
analysis that FIGO stage IIIC TP53( ) group showed higher
probability of death when treated with CAP chemotherapy
(Table 4). The only factor that consequently influenced OS in the
FIGO IIIC group was patient age (Table 4).
Complete remission and platinum sensitivity
Complete remission (CR) was achieved in 120 patients (52%),
while PS response (CR with DFS longer than 6 months) was
achieved in 99 of 229 patients (43%). Clinical parameters were the
strongest predictors of CR (Table 5) and the only predictors of PS
Table 3 Overall survival (risk of death) in the whole group of ovarian carcinomas, and in the TP53(+) and TP53( ) group (Cox’s proportional hazards
model)
TP53(–) and (+) N=229, 168 deaths TP53(–) N=94, 73 deaths TP53(+) N=135, 95 deaths
RR
95% CI
for RR P RR
95% CI
for RR P RR
95% CI
for RR P
Age
X52 vs o52 1.9 [1.4, 2.6] o0.001 0.11 1.9 [1.3, 3.0] 0.002
FIGO 0.011 0.045 0.17
IIB, IIC vs IV 0.21 [0.08, 0.55] 0.001 0.09 [0.01, 0.68] 0.020
IIIA, IIIB vs IV 0.55 [0.31, 0.97] 0.04 0.47 [0.23, 0.98] 0.045
IIIC vs IV 0.23 0.28
Residual tumour
>2cm vs 0–2cm 1.8 [1.2, 2.6] 0.004 0.28 2.4 [1.6, 3.8] 0.0001
Chemotherapy
CAP vs CP 1.4 [0.98, 1.9] 0.07 1.6 [0.93, 2.7] 0.09 0.51
Histological type 0.06 0.37 0.79
Endo/clear vs ser 1.7 [1.0, 2.7] 0.04
Undiff/other vs ser 0.16
Endo/clear=endometrioid or clear cell; ser=serous; undiff/other=undifferentiated or other types.
Table 4 Overall survival (risk of death) in FIGO IIIC ovarian carcinomas, and in the group IIIC divided according to TP53 status (Cox’s proportional
hazards model)
TP53(–) and (+) N=129, 101 deaths TP53(–) N=51, 41 deaths TP53(+) N=78, 60 deaths
RR
95% CI
for RR P RR
95% CI
for RR P RR
95% CI
for RR P
Age
X52 vs o52 3.1 [2.0, 4.7] o0.001 3.1 [1.6, 5.9] o0.001 2.9 [1.7, 5.0] o0.001
Chemotherapy
CAP vs CP 0.096 2.2 [1.0, 4.6] 0.04 0.46
Table 5 Probability of CR in the whole group of ovarian carcinomas, and in the TP53(+) and TP53( ) group (logistic regression model)
TP53(–) and (+) N=229, 120 CR TP53(–) N=94, 46 CR TP53(+) N=135, 74 CR
OR
95% CI
for OR P OR
95% CI
for OR P OR
95% CI
for OR P
Age
X52 vs o52 0.49 [0.27, 0.89] 0.019 0.36 [0.14, 0.88] 0.026 0.28
Residual tumour
>2cm vs 0–2cm 0.16 [0.08, 0.33] o0.001 0.27 [0.11, 0.68] 0.005 0.10 [0.04, 0.22] o0.001
BAX
High (+) vs low (+) 0.53 [0.29, 0.99] 0.047 0.52 0.13
BCL-2
(+) vs ( ) 0.14 0.4 [0.16, 1.01] 0.05 0.99
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proteins, too.
Complete remission status was associated with small RT size in
all three groups analysed (Table 5). It was also associated with
lower patient age in the whole group and in the TP53( ) group.
Complete remission status was associated with low BAX staining in
the whole group, and with negative BCL-2 staining in the TP53( )
group. The only factor that influenced probability of CR in the
TP53(+) group was RT size (Table 3).
Platinum sensitivity showed associations with small RT at the
same P level as CR; PS was also associated with FIGO stage IIB or
IIC in the whole group (P¼0.02) and in the TP53(+) group
(P¼0.05), as well as with patient age in the whole group only
(P¼0.017). Low BAX expression showed a tendency to increase
probability of PS in the TP53( ) group, but it was at the border of
significance (P¼0.07). Other factors did not influence response to
chemotherapy.
Disease-free survival analysis
In the whole group of patients with CR (N¼120, 92 with
recurrences), DFS was influenced by FIGO stage only (P¼0.0005).
In the TP53(+) group (74 with CR, 58 with recurrences) BAX
expression was the strongest or the only (in FIGO IIIC, P¼0.02)
prognostic indicator of DFS. In this group, DFS was longer with
lower FIGO stage (P¼0.01) and with high BAX expression
(P¼0.005, RR¼0.45, 95% CI for RR: [0.25, 0.78]). This tendency
has been confirmed in the TP53(+) FIGO IIIC group (39 with CR,
32 with recurrences), that is after elimination of clinical stage
parameter: strong (not generally high) BAX expression had
positive influence on DFS (P¼0.02, RR¼0.39, 95% CI for RR:
[0.17, 0.88]). Strong BAX expression in the TP53(+) group was the
only parameter that influenced DFS in FIGO IIIC group.
In the TP53( ) group (46 with CR, 34 with recurrences) DFS
was longer with lower residual tumour, at the border of
significance (P¼0.06). The other factors included into the analysis
did not influence DFS time.
DISCUSSION
In cell line studies, BCL-2, BAX, as well as novel MEK1 protein
levels have strong influence on ovarian cancer response
to cisplatin-based chemotherapy. With a single exception related
to BCL-2 expression (Mano et al, 1999), such associations have
not been demonstrated clinically. To our knowledge, this is the
first evidence of influence of BAX and BCL-2 expression on CR in
ovarian cancer patients, confirmed by multivariate analysis.
BAX expression, in contrast to its apoptosis promoter function
and similarly to BCL-2 expression had negative impact on CR.
Similar discrepancy between biological function of apoptosis
proteins and their clinical significance has been previously
observed by Marx et al (1997) who found a bad prognostic
significance of BAX expression, and a good one of BCL-2
expression.
In the current study, negative impact of BCL-2 expression on CR
was demonstrated in the TP53-negative carcinomas only, con-
firming our hypothesis that TP53-positive and TP53-negative
ovarian carcinomas differ in clinical significance of apoptosis
proteins interacting with TP53 in tumour response to cisplatin-
based chemotherapy. In subgroups related to the TP53 status,
BCL-2 and BAX demonstrated an influence on CR or DFS, which
was not seen in all tumours. Among other studies evaluating
predictive significance of BCL-2 (Herod et al, 1996; Mano et al,
1999; Schuyer et al, 2001), including two published by Baekelandt
et al (1999, 2000) on a comparable number of ovarian carcinomas,
only Mano et al (1999) noticed higher frequency of CR in patients
with BCL-2 negative tumours.
In regard to BAX expression, a few studies have addressed the
issue of its clinical significance in advanced stage ovarian
carcinomas; however, associations with CR or DFS have not been
observed (Marx et al, 1997; Baekelandt et al, 2000; Sengupta et al,
2000; Schuyer et al, 2001). Recently, Schuyer et al (2001) found an
association of BAX expression with progression-free survival.
Interestingly, TP53-positive and TP53-negative carcinomas
demonstrated striking differences not only in relation to
immunohistochemical markers, but also to clinical parameters.
After division of ovarian carcinomas into TP53-negative and TP53-
positive, prognostic significance of patient age, FIGO stage,
residual tumour size and histological tumour type either
disappeared or became weaker or stronger, depending on the
group. As a factor of OS, FIGO stage appeared to be an alternative
to patient age. This has been supported by the analysis of FIGO
IIIC group only, in which patient age was a constant prognostic
factor irrespective of TP53 status. Apparently, the differing results
for the TP53-negative and TP53-positive carcinomas were not
influenced by differences in clinicopathological characteristics,
since both groups were very similar. Nevertheless, the tendencies
revealed by subgroup analysis should be confirmed on larger
population.
Despite the novel findings related to TP53 and apoptosis
proteins, clinical parameters were the only factors of OS, the
strongest predictors of CR and the only predictors of platinum
sensitivity. In particular, residual tumour size was a constant and
important parameter influencing CR. The strong impact of clinical
parameters on clinical end points in our analysis is in agreement
with other studies (Makar et al, 1995; Partridge et al, 1996;
Eisenhauer et al, 1999). Usually, immunohistochemical markers
present lower associations with clinical end points than clinical
parameters (Diebold et al, 1996; Herod et al, 1996; Baekelandt et al,
1999, 2000; Mano et al, 1999; Geisler et al, 2000; Reles et al, 2001;
Schuyer et al, 2001). In our analysis, the only exception was the
positive influence of high BAX expression on DFS in patients with
TP53-positive ovarian carcinomas – it was stronger than that of the
FIGO stage. After elimination of stage factor (TP53-positive FIGO
IIIC group only) BAX expression was the only parameter that
influenced DFS.
Evaluation of clinical significance of MEK1 and TP53 expression
has generally brought negative results, confirming that observa-
tions from cell line studies cannot be directly referred to clinical
situations. As far as TP53 is concerned, in the literature there are
few studies on clinical significance of TP53 protein accumulation
in large groups of advanced stage ovarian carcinomas (Hartmann
et al, 1994; Eltabbakh et al, 1997; Baekelandt et al, 1999; Ferrandina
et al, 1999; Shahin et al, 2000; Reles et al, 2001). Two of three of
those research groups who related TP53 protein accumulation to
tumour response to platinum-based chemotherapy have found
better response in TP53-negative tumours (Ferrandina et al, 1999;
Reles et al, 2001). Baeklandt et al (1999) have shown a prognostic
but not predictive significance of TP53 protein accumulation,
while other authors did not find any clinical significance of the
TP53 protein (Hartmann et al, 1994; Eltabbakh et al, 1997; Shahin
et al, 2000). Similarly, in our study TP53 expression by itself did
not show any clinical significance. Interestingly though, our results
suggest that impaired TP53 protein function may level or enhance
prognostic or predictive significance of other factors. Platinum
compounds and taxanes that are currently applied as a standard
treatment in ovarian cancer patients have different molecular
targets. There is a pilot study showing that tumours with TP53
gene mutations show better response to paclitaxel than tumours
with wt TP53 (Lavarino et al, 2000); the reverse is observed
by some authors in relation to cisplatin (as above). It seems
that separate evaluation of TP53-positive and TP53-negative
subgroups may help to identify molecular profiles of tumours,
which will show differential response to different chemotherapeu-
tic regimens.
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